Home > Journals > Minerva Cardiology and Angiology > Past Issues > Articles online first > Minerva Cardiology and Angiology 2021 Apr 07

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Minerva Cardiology and Angiology 2021 Apr 07

DOI: 10.23736/S2724-5683.20.05413-4

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Targeting "diabetic" coronary stenosis merging the properties of sirolimus coated balloon with sirolimus eluting stent

Luca TESTA 1 , Matteo CASENGHI 1, Antonio POPOLO RUBBIO 1, Sameer DANI 2, Devang DESAI 3, Rashmit PANDYA 2, Pritesh PAREKH 4, Nirav BHALANI 5, Arvind SHARMA 5, Chirag SETH 5, Francesco BEDOGNI 1

1 Department of Cardiology, IRCCS Policlinico S. Donato, Milan, Italy; 2 Life Care Institute of Medical Sciences & Research & Apollo Hospitals, Ahmedabad, Gujarat, India; 3 Mahavir Hospitals, Surat, Gujarat, India; 4 Care Hospitals, Surat, Gujarat, India; 5 Rhythm Heart Institute, Baroda, Gujarat, India


PDF


BACKGROUND: Patients with diabetes mellitus (DM) represents a challenging subset of population as they experience worse outcomes after percutaneous coronary intervention than patients without diabetes. We evaluated the 2-year efficacy and safety profile of the Abluminus DES+ in patients with diabetes within the population enrolled in the large multicenter en-ABL e-registry.
METHODS: Multicenter, prospective, all-comers registry performed in 31 centers in India. We analyze patients according to the diagnosis of DM and insulin dependency (ID or Non-ID): non-DM (1.641 patients), NIDDM (721 patients), IDDM (138 patients). The primary endpoint was a composite of device-oriented major adverse cardiac events (MACE): cardiac death, target vesselrelated myocardial infarction (MI), and ischemia-driven target lesion revascularization (TLR)/ target vessel revascularization (TVR) at 2-year. Stent thrombosis (ST) at any time point was also recorded.
RESULTS: The MACE rate at 2-year follow-up was 3.0 %in the overall population with DM patients showing a higher rate of primary endpoint compared to non-DM (4.4 % vs 2.4 %, p=0.025). Rate of cardiac death was actually low and consistent between the 2 groups (1.7 % vs 0.9 %, p=0.100). At 2-year, the rate of ST was 0.9 % in DM patients versus 0.5 % in non-DM, p=0.213.
CONCLUSIONS: At 2-year, the Abluminus DES+ technology that merges the features of a sirolimus coated balloon with those of a bioresorbable polymer drug eluting stent appears to be safe and effective. This safety/efficacy profile was consistent in patients with or without DM.


KEY WORDS: Diabetes mellitus; Sirolimus Eluting stent; Biodegradable polymer; Insulin dependent diabetes mellitus; Stent thrombosis

top of page